Publications by authors named "M Ebinger"
Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae, and health-related quality of life (HRQoL) of this treatment are limited, this retrospective analysis aimed to explore these.
View Article and Find Full Text PDFBackground And Objectives: Data from randomized trials on the treatment effect of pure thrombolysis in patients with vessel occlusion are lacking. We examined data from a corresponding subsample of patients from the multicenter, randomized, placebo-controlled WAKE-UP trial to determine whether MRI-guided IV thrombolysis with alteplase in unknown-onset ischemic stroke benefits patients presenting with vessel occlusion.
Methods: Patients with an acute ischemic lesion visible on MRI diffusion-weighted imaging but no marked parenchymal hyperintensity on fluid-attenuated inversion recovery images were randomized to treatment with IV alteplase or placebo.
Article Synopsis
- Blood-brain barrier disruption in acute ischemic stroke is linked to complications, with GLOS indicating issues in the blood-ocular barrier.
- In a study of WAKE-UP trial patients, 29% showed GLOS, significantly more than the 7% with HARM.
- GLOS presence was associated with factors like age, renal function, and white matter hyperintensity but did not correlate with hemorrhagic transformation or functional outcomes.
Objective: Posterior fossa pediatric low-grade glioma involving the brainstem and cerebellar peduncles (BS-pLGG) are a subgroup with higher risks at surgery. We retrospectively analyzed the role of surgery in the interdisciplinary armamentarium of treatment options in our institutional series of BS-pLGG with various degrees of brainstem involvement.
Material And Methods: We analyzed data of 52 children with BS-pLGG after surgical intervention for clinical/molecular characteristics, neurological outcome, factors influencing recurrence/progression pattern, and tumor volumetric analysis of exclusively surgically treated patients to calculate tumor growth velocity (TGV).
Article Synopsis
- Targeting acute myeloid leukemia (AML) with CAR-T cells is complex due to the widespread expression of AML antigens in healthy cells and the variability between different patients and even within the same patient's tumor cells.
- Single-cell analysis of 30 pediatric AML samples highlighted CD33, CD38, CD371, IL1RAP, and CD123 as key antigens, underscoring the need for multiple targeting strategies.
- The study introduces a modular Adapter CAR platform that allows for flexible and effective targeting of these antigens, showing that combining targets can lead to better treatment outcomes in heterogeneous AML populations.